Race Oncology Ltd (ASX: RAC)The Race Oncology share price is up...

Race Oncology Ltd (ASX: RAC)

The Race Oncology share price is up 18% to $2.08. Investors have been buying this clinical stage biopharmaceutical company's shares after the United States Food and Drug Administration (FDA) extended Rare Paediatric Disease Designation (RPDD) to RC220 bisantrene for the treatment of childhood subtypes of acute myeloid leukemia (AML). This qualifies a sponsor eligible to receive a Priority Review Voucher (PRV) from the FDA at the time of marketing approval or authorisation for drug in the paediatric rare disease area. PRVs are transferable and very valuable. Management notes that two PRVs have been sold in recent times for US$110 million.

********.au /2024/06/18/why-capitol-health-infratil-newmont-and-race-oncology-shares-are-charging-higher/